To date, no treatment can slow or stop the progression of Parkinson's disease or multiple system atrophy, two neurodegenerative diseases linked to the accumulation of alpha-synuclein in the brain. Therapeutic solutions capable of modifying the natural progression of the disease are now highly anticipated.

Our ambition is to develop a disease-modifying therapy (DMT) for these two diseases that slows or even stabilizes their progression by restoring the ability of affected cells to degrade misfolded alpha-synuclein proteins and their aggregates which contribute to neuronal death.

This DMT would profoundly transform patient care by targeting the cause and the progression, rather than just the symptoms. It would slow neurodegeneration, preserving motor and cognitive functions for longer. Patients would thus maintain a better quality of life and prolonged independence.

Initial in vivo data indicate that our drug candidate has a neuroprotective effect. This project was born from a collaboration between the Institute of Neurodegenerative Diseases (IMN) and the laboratory of organic polymer chemistry (LCPO) in Bordeaux.

Description du poste

As the future CEO, you will be responsible for defining the company's development strategy in all its dimensions (market, finance, product, etc.) in collaboration with the founders, with the following main missions :

• Building and managing the company's business model to guarantee its profitability;
• Securing the necessary funding to support the development and commercialization of this new treatment by responding to calls for projects and competitions and raising funds from investors;
• Formalizing the regulatory preclinical roadmap and managing the company's business plan;
• Structuring the team and industrial partnerships (CRO, CDMO, pharmaceutical clients);

Profil recherché

Desired Profile :

• PhD in a Life Sciences or Chemistry field, preferably in the neurosciences or formulation chemistry
• Proven experience (5+ years) in general management, industrial development, or scale-up within the pharma/biotech sector.
• Experience in fundraising (preseed/seed) or negotiating strategic partnerships (industrial, commercial, and distribution partners).
• Strong communication skills to effectively convey business strategies and capabilities internally and externally, and the ability to communicate effectively with partners, investors, and clients.
• A strong interest in R&D challenges and industrial innovation, with a keen entrepreneurial mindset.

Differentiating Assets :

• Experience in fundraising or industrial partnerships
• Successful experience in regulatory preclinical and/or clinical development of therapeutic treatment
• Strong network within the pharmaceutical industry, CRO, CDMOs, or VCs
• Experience in the neurology/neurodegeneration field is required
• Knowledge or experience with nanoparticles/nanovectors is a plus